摘要
本文通过分析福建省药械联合采购中心2018年7月至2019年12月“4+7”相关药品的采购数据,按中选类别、医疗机构所属统筹区分类统计用药频度DDDs、日均用药金额DDC,并计算药品价格指数DPI,以评估福建全省跟进“4+7”试点政策的实施效果。并提出建议:国家试点创新改革结合福建特色经验有利于全省推进并取得显著成效;推进“4+7”试点政策应加强对高等级医院非中选药品与替代药品的价格与数量监测;基于医保采购数据的药品价格指数可用于比较不同统筹区政策实施效果。
This paper analyzes the purchasing data of"4+7"related drugs from July 2018 to December 2019 of Fujian Pharmaceutical&Consumables Procurement Center,calculates DDDs,DDC and drug price index(DPI)to evaluate the implementation eff ect of"4+7"policy in Fujian.Suggestions are put forward as follows:the national pilot innovation reform combined with Fujian's characteristic experience is conducive to the promotion of the whole province and has achieved remarkable results;to promote the"4+7"policy,we should strengthen the price and quantity monitoring of non selected drugs and alternative drugs in high-level hospitals;the DPI based on medical insurance procurement data can be used to compare the implementation eff ect of policies in diff erent overall planning areas.
作者
叶顺萍
康洽福
高锦娟
陈庆锋
胡世明
蔡和超
丁榕芳
Ye Shunping;Kang Qiafu;Gao Jinjuan;Chen Qingfeng;Hu Shiming;Cai Hechao;Ding Rongfang(Fujian Provincial Government Hospital,Fuzhou,350001;Fuzhou Medical Insurance Management Center,China Railway Nanchang Bureau Group Co.,Ltd.,Fuzhou,350013;The Second Affi liated Hospital of Fujian Traditional Chinese Medicine University,Fuzhou,350003;Fujian Provincial Hospital,Fuzhou,350001;School of Finance,Fujian Jiangxia University,Fuzhou,350108;Fujian Provincial Health Commission,Fuzhou,350003;Fujian Social Medical Insurance Association,Fuzhou,350003)
出处
《中国医疗保险》
2020年第8期35-39,共5页
China Health Insurance
基金
福建省社会医疗保险协会2020年度委托课题:福建省药品集中带量采购政策实践研究。
